MINK THERAPEUTICS INC (INKT) Stock Price, Quote, News and Overview
NASDAQ:INKT - Nasdaq - US6036931029 - Common Stock - Currency: USD
INKT Quote, Performance and Key Statistics
MINK THERAPEUTICS INC
NASDAQ:INKT (1/30/2025, 11:30:36 AM)
6.39
-0.21 (-3.18%)
The current stock price of INKT is 6.39 USD. In the past month the price increased by 14.78%. In the past year, price decreased by -26.59%.
INKT Latest News, Press Releases and Analysis
Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
These stocks are moving in today's session
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
The market is filled with gapping stocks in Tuesday's session.
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development...
INKT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.34 | 310.45B | ||
| AMGN | AMGEN INC | 14.73 | 152.21B | ||
| GILD | GILEAD SCIENCES INC | 21.71 | 119.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 865.88 | 113.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.15 | 75.64B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.58B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.85B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.39B | ||
| NTRA | NATERA INC | N/A | 22.98B | ||
| BIIB | BIOGEN INC | 8.99 | 21.38B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.32B |
Related stock screener links
About INKT
Company Profile
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 31 full-time employees. The company went IPO on 2021-10-15. The company is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Company Info
MINK THERAPEUTICS INC
149 Fifth Avenue, Suite 500
New York City NEW YORK US
Employees: 31
Company Website: https://www.minktherapeutics.com
Investor Relations: https://investor.minktherapeutics.com/
Phone: 12129948250
INKT FAQ
What is the stock price of INKT?
The current stock price of INKT is 6.39 USD.
What is the symbol for MINK THERAPEUTICS INC stock?
The exchange symbol of MINK THERAPEUTICS INC is INKT and it is listed on the Nasdaq exchange.
On which exchange is INKT stock listed?
INKT stock is listed on the Nasdaq exchange.
Is INKT a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for INKT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of INKT.
Does INKT stock pay dividends?
INKT does not pay a dividend.
What is the Price/Earnings (PE) ratio of INKT?
INKT does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.39).
What is the Short Interest ratio of INKT stock?
The outstanding short interest for INKT is 1.22% of its float.
INKT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to INKT. When comparing the yearly performance of all stocks, INKT is a bad performer in the overall market: 85.19% of all stocks are doing better.
INKT Financial Highlights
Over the last trailing twelve months INKT reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS increased by 46.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -186.86% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
INKT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to INKT. The Buy consensus is the average rating of analysts ratings from 10 analysts.